Search Menu
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information
Search Scholarly Publications

Title: Optimal combinations of broadly neutralizing antibodies for prevention and treatments of HIV-1 clade C infection

Abstract

In this study, the identification of a new generation of potent broadly neutralizing HIV-1 antibodies (bnAbs) has generated substantial interest in their potential use for the prevention and/or treatment of HIV-1 infection. While combinations of bnAbs targeting distinct epitopes on the viral envelope (Env) will likely be required to overcome the extraordinary diversity of HIV-1, a key outstanding question is which bnAbs, and how many, will be needed to achieve optimal clinical benefit. We assessed the neutralizing activity of 15 bnAbs targeting four distinct epitopes of Env, including the CD4-binding site (CD4bs), the V1/V2-glycan region, the V3-glycan region, and the gp41 membrane proximal external region (MPER), against a panel of 200 acute/early clade C HIV-1 Env pseudoviruses. A mathematical model was developed that predicted neutralization by a subset of experimentally evaluated bnAb combinations with high accuracy. Using this model, we performed a comprehensive and systematic comparison of the predicted neutralizing activity of over 1,600 possible double, triple, and quadruple bnAb combinations. The most promising bnAb combinations were identified based not only on breadth and potency of neutralization, but also other relevant measures, such as the extent of complete neutralization and instantaneous inhibitory potential (IIP). By this set of criteria, triplemore » and quadruple combinations of bnAbs were identified that were significantly more effective than the best double combinations, and further improved the probability of having multiple bnAbs simultaneously active against a given virus, a requirement that may be critical for countering escape in vivo. These results provide a rationale for advancing bnAb combinations with the best in vitro predictors of success into clinical trials for both the prevention and treatment of HIV-1 infection.« less

Authors:
 [1];  [2];  [3];  [4];  [4];  [4];  [4];  [3];  [1];  [1];  [5];  [5];  [6];  [6];  [7];  [8];  [4];  [9];  [6];  [10] more »;  [5];  [1];  [4] « less
+ Show Author Affiliations
  1. Los Alamos National Lab. (LANL), Los Alamos, NM (United States)
  2. Los Alamos National Lab. (LANL), Los Alamos, NM (United States); Santa Fe Institute, Santa Fe, NM (United States)
  3. Univ. of Cape Town and NHLS, Cape Town (South Africa)
  4. Beth Israel Deaconess Medical Center, Boston, MA (United States)
  5. Duke Univ. Medical Center, Durham, NC (United States)
  6. NIAID, NIH, Bethesda, MD (United States)
  7. Univ. of KwaZulu-Natal, Durban (South Africa)
  8. The Scripps Research Institute, La Jolla, CA (United States)
  9. The Rockefeller Univ., New York, NY (United States)
  10. Univ. of KwaZulu-Natal, Durban (South Africa); Univ. of the Witwatersrand, Johannesburg (South Africa)
Publication Date:
Research Org.:
Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1291229
Report Number(s):
LA-UR-16-20914
Journal ID: ISSN 1553-7374
Grant/Contract Number:  
AC52-06NA25396
Resource Type:
Accepted Manuscript
Journal Name:
PLoS Pathogens
Additional Journal Information:
Journal Volume: 12; Journal Issue: 3; Journal ID: ISSN 1553-7374
Publisher:
Public Library of Science
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES; biological science; HIV-1; antibodies; antiretrovirals; complement system; immunotherapy; blood plasma; microbial genetics; pharmacokinetics

Citation Formats

Wagh, Kshitij, Bhattacharya, Tanmoy, Williamson, Carolyn, Robles, Alex, Bayne, Madeleine, Garrity, Jetta, Rist, Michael, Rademeyer, Cecilia, Yoon, Hyejin, Lapedes, Alan Scott, Gao, Hongmei, Greene, Kelli, Louder, Mark K., Kong, Rui, Karim, Salim Abdool, Burton, Dennis R., Barouch, Dan H., Nussenzweig, Michael C., Mascola, John R., Morris, Lynn, Montefiori, David, Korber, Bette Tina, and Seamon, Michael S. Optimal combinations of broadly neutralizing antibodies for prevention and treatments of HIV-1 clade C infection. United States: N. p., 2016. Web. doi:10.1371/journal.ppat.1005520.
Copy to clipboard
Wagh, Kshitij, Bhattacharya, Tanmoy, Williamson, Carolyn, Robles, Alex, Bayne, Madeleine, Garrity, Jetta, Rist, Michael, Rademeyer, Cecilia, Yoon, Hyejin, Lapedes, Alan Scott, Gao, Hongmei, Greene, Kelli, Louder, Mark K., Kong, Rui, Karim, Salim Abdool, Burton, Dennis R., Barouch, Dan H., Nussenzweig, Michael C., Mascola, John R., Morris, Lynn, Montefiori, David, Korber, Bette Tina, & Seamon, Michael S. Optimal combinations of broadly neutralizing antibodies for prevention and treatments of HIV-1 clade C infection. United States. https://doi.org/10.1371/journal.ppat.1005520
Copy to clipboard
Wagh, Kshitij, Bhattacharya, Tanmoy, Williamson, Carolyn, Robles, Alex, Bayne, Madeleine, Garrity, Jetta, Rist, Michael, Rademeyer, Cecilia, Yoon, Hyejin, Lapedes, Alan Scott, Gao, Hongmei, Greene, Kelli, Louder, Mark K., Kong, Rui, Karim, Salim Abdool, Burton, Dennis R., Barouch, Dan H., Nussenzweig, Michael C., Mascola, John R., Morris, Lynn, Montefiori, David, Korber, Bette Tina, and Seamon, Michael S. Wed . "Optimal combinations of broadly neutralizing antibodies for prevention and treatments of HIV-1 clade C infection". United States. https://doi.org/10.1371/journal.ppat.1005520. https://www.osti.gov/servlets/purl/1291229.
Copy to clipboard
@article{osti_1291229,
title = {Optimal combinations of broadly neutralizing antibodies for prevention and treatments of HIV-1 clade C infection},
author = {Wagh, Kshitij and Bhattacharya, Tanmoy and Williamson, Carolyn and Robles, Alex and Bayne, Madeleine and Garrity, Jetta and Rist, Michael and Rademeyer, Cecilia and Yoon, Hyejin and Lapedes, Alan Scott and Gao, Hongmei and Greene, Kelli and Louder, Mark K. and Kong, Rui and Karim, Salim Abdool and Burton, Dennis R. and Barouch, Dan H. and Nussenzweig, Michael C. and Mascola, John R. and Morris, Lynn and Montefiori, David and Korber, Bette Tina and Seamon, Michael S.},
abstractNote = {In this study, the identification of a new generation of potent broadly neutralizing HIV-1 antibodies (bnAbs) has generated substantial interest in their potential use for the prevention and/or treatment of HIV-1 infection. While combinations of bnAbs targeting distinct epitopes on the viral envelope (Env) will likely be required to overcome the extraordinary diversity of HIV-1, a key outstanding question is which bnAbs, and how many, will be needed to achieve optimal clinical benefit. We assessed the neutralizing activity of 15 bnAbs targeting four distinct epitopes of Env, including the CD4-binding site (CD4bs), the V1/V2-glycan region, the V3-glycan region, and the gp41 membrane proximal external region (MPER), against a panel of 200 acute/early clade C HIV-1 Env pseudoviruses. A mathematical model was developed that predicted neutralization by a subset of experimentally evaluated bnAb combinations with high accuracy. Using this model, we performed a comprehensive and systematic comparison of the predicted neutralizing activity of over 1,600 possible double, triple, and quadruple bnAb combinations. The most promising bnAb combinations were identified based not only on breadth and potency of neutralization, but also other relevant measures, such as the extent of complete neutralization and instantaneous inhibitory potential (IIP). By this set of criteria, triple and quadruple combinations of bnAbs were identified that were significantly more effective than the best double combinations, and further improved the probability of having multiple bnAbs simultaneously active against a given virus, a requirement that may be critical for countering escape in vivo. These results provide a rationale for advancing bnAb combinations with the best in vitro predictors of success into clinical trials for both the prevention and treatment of HIV-1 infection.},
doi = {10.1371/journal.ppat.1005520},
journal = {PLoS Pathogens},
number = 3,
volume = 12,
place = {United States},
year = {Wed Mar 30 00:00:00 EDT 2016},
month = {Wed Mar 30 00:00:00 EDT 2016}
}
Copy to clipboard
Journal Article:
Free Publicly Available Full Text
Publisher's Version of Record
https://doi.org/10.1371/journal.ppat.1005520
Copyright Statement
Other availability
Search WorldCat Search WorldCat to find libraries that may hold this journal
Citation Metrics:
Cited by: 127 works
Citation information provided by
Web of Science
Save / Share:
Export Metadata
Save to My Library
You must Sign In or Create an Account in order to save documents to your library.

Works referenced in this record:

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo
journal, October 2012

  • Moldt, B.; Rakasz, E. G.; Schultz, N.
  • Proceedings of the National Academy of Sciences, Vol. 109, Issue 46
  • DOI: 10.1073/pnas.1214785109

Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
journal, August 2013

  • Kwong, Peter D.; Mascola, John R.; Nabel, Gary J.
  • Nature Reviews Immunology, Vol. 13, Issue 9
  • DOI: 10.1038/nri3516

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
journal, September 2012

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
journal, November 2011

  • McLellan, Jason S.; Pancera, Marie; Carrico, Chris
  • Nature, Vol. 480, Issue 7377
  • DOI: 10.1038/nature10696

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface
journal, September 2014

  • Huang, Jinghe; Kang, Byong H.; Pancera, Marie
  • Nature, Vol. 515, Issue 7525
  • DOI: 10.1038/nature13601

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
journal, April 2015

  • Caskey, Marina; Klein, Florian; Lorenzi, Julio C. C.
  • Nature, Vol. 522, Issue 7557
  • DOI: 10.1038/nature14411

Structural Delineation of a Quaternary, Cleavage-Dependent Epitope at the gp41-gp120 Interface on Intact HIV-1 Env Trimers
journal, May 2014

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice
journal, September 2013

  • Horwitz, J. A.; Halper-Stromberg, A.; Mouquet, H.
  • Proceedings of the National Academy of Sciences, Vol. 110, Issue 41
  • DOI: 10.1073/pnas.1315295110

Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein
journal, July 2012

  • Klein, Florian; Gaebler, Christian; Mouquet, Hugo
  • The Journal of Experimental Medicine, Vol. 209, Issue 8
  • DOI: 10.1084/jem.20120423

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
journal, June 2009

  • Hessell, Ann J.; Poignard, Pascal; Hunter, Meredith
  • Nature Medicine, Vol. 15, Issue 8
  • DOI: 10.1038/nm.1974

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
journal, November 1994

A Blueprint for HIV Vaccine Discovery
journal, October 2012

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
journal, August 2014

  • Ko, Sung-Youl; Pegu, Amarendra; Rudicell, Rebecca S.
  • Nature, Vol. 514, Issue 7524
  • DOI: 10.1038/nature13612

Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV
journal, May 2014

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor
journal, July 2014

Antibody to gp41 MPER Alters Functional Properties of HIV-1 Env without Complete Neutralization
journal, July 2014

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9
journal, February 2013

  • Julien, Jean-Philippe; Lee, Jeong Hyun; Cupo, Albert
  • Proceedings of the National Academy of Sciences, Vol. 110, Issue 11
  • DOI: 10.1073/pnas.1217537110

Strategies to guide the antibody affinity maturation process
journal, April 2015

Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice
journal, August 2014

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
journal, June 2008

  • Shen, Lin; Peterson, Susan; Sedaghat, Ahmad R.
  • Nature Medicine, Vol. 14, Issue 7
  • DOI: 10.1038/nm1777

Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies
journal, September 2015

  • Webb, Nicholas E.; Montefiori, David C.; Lee, Benhur
  • Nature Communications, Vol. 6, Issue 1
  • DOI: 10.1038/ncomms9443

Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1
journal, July 2014

  • Sarzotti-Kelsoe, Marcella; Bailer, Robert T.; Turk, Ellen
  • Journal of Immunological Methods, Vol. 409
  • DOI: 10.1016/j.jim.2013.11.022

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
journal, July 2010

Variable Loop Glycan Dependency of the Broad and Potent HIV-1-Neutralizing Antibodies PG9 and PG16
journal, August 2010

  • Doores, Katie J.; Burton, Dennis R.
  • Journal of Virology, Vol. 84, Issue 20
  • DOI: 10.1128/JVI.00552-10

Immunologic strategies for HIV-1 remission and eradication
journal, July 2014

Broadly Neutralizing Anti-HIV Antibody 4E10 Recognizes a Helical Conformation of a Highly Conserved Fusion-Associated Motif in gp41
journal, February 2005

A method for identification of HIV gp140 binding memory B cells in human blood
journal, April 2009

  • Scheid, Johannes F.; Mouquet, Hugo; Feldhahn, Niklas
  • Journal of Immunological Methods, Vol. 343, Issue 2
  • DOI: 10.1016/j.jim.2008.11.012

Antibodies in HIV-1 Vaccine Development and Therapy
journal, September 2013

Fc receptor but not complement binding is important in antibody protection against HIV
journal, September 2007

  • Hessell, Ann J.; Hangartner, Lars; Hunter, Meredith
  • Nature, Vol. 449, Issue 7158
  • DOI: 10.1038/nature06106

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies
journal, October 2012

  • Mouquet, H.; Scharf, L.; Euler, Z.
  • Proceedings of the National Academy of Sciences, Vol. 109, Issue 47
  • DOI: 10.1073/pnas.1217207109

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
journal, October 2013

  • Shingai, Masashi; Nishimura, Yoshiaki; Klein, Florian
  • Nature, Vol. 503, Issue 7475
  • DOI: 10.1038/nature12746

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
journal, October 2011

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
journal, October 2013

  • Barouch, Dan H.; Whitney, James B.; Moldt, Brian
  • Nature, Vol. 503, Issue 7475
  • DOI: 10.1038/nature12744

B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study
journal, May 2012

  • Haynes, Barton F.; Kelsoe, Garnett; Harrison, Stephen C.
  • Nature Biotechnology, Vol. 30, Issue 5
  • DOI: 10.1038/nbt.2197

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors
journal, June 2015

Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
journal, September 2014

Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies
journal, September 2012

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120
journal, May 2013

  • Kong, Leopold; Lee, Jeong Hyun; Doores, Katie J.
  • Nature Structural & Molecular Biology, Vol. 20, Issue 7
  • DOI: 10.1038/nsmb.2594

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies
journal, March 2014

  • Doria-Rose, Nicole A.; Schramm, Chaim A.; Gorman, Jason
  • Nature, Vol. 509, Issue 7498
  • DOI: 10.1038/nature13036

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing
journal, August 2011

Statistical significance for genomewide studies
journal, July 2003

  • Storey, J. D.; Tibshirani, R.
  • Proceedings of the National Academy of Sciences, Vol. 100, Issue 16, p. 9440-9445
  • DOI: 10.1073/pnas.1530509100

Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1
journal, June 2010

  • Pejchal, R.; Walker, L. M.; Stanfield, R. L.
  • Proceedings of the National Academy of Sciences, Vol. 107, Issue 25
  • DOI: 10.1073/pnas.1004600107

Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection
journal, March 2015

  • Saunders, Kevin O.; Pegu, Amarendra; Georgiev, Ivelin S.
  • Journal of Virology, Vol. 89, Issue 11
  • DOI: 10.1128/JVI.00210-15

Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16
journal, May 2013

  • Pancera, Marie; Shahzad-ul-Hussan, Syed; Doria-Rose, Nicole A.
  • Nature Structural & Molecular Biology, Vol. 20, Issue 7
  • DOI: 10.1038/nsmb.2600

Antibody 8ANC195 Reveals a Site of Broad Vulnerability on the HIV-1 Envelope Spike
journal, May 2014

Broad neutralization coverage of HIV by multiple highly potent antibodies
journal, September 2011

  • Walker, Laura M.; Huber, Michael; Doores, Katie J.
  • Nature, Vol. 477, Issue 7365
  • DOI: 10.1038/nature10373

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
journal, February 2000

  • Mascola, John R.; Stiegler, Gabriela; VanCott, Thomas C.
  • Nature Medicine, Vol. 6, Issue 2
  • DOI: 10.1038/72318

HIV-1 neutralizing antibodies: understanding nature's pathways
journal, June 2013

  • Mascola, John R.; Haynes, Barton F.
  • Immunological Reviews, Vol. 254, Issue 1
  • DOI: 10.1111/imr.12075

The Role of Antibodies in HIV Vaccines
journal, March 2010

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
journal, July 2011

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
journal, March 2009

  • Scheid, Johannes F.; Mouquet, Hugo; Feldhahn, Niklas
  • Nature, Vol. 458, Issue 7238
  • DOI: 10.1038/nature07930

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants
journal, November 2014

  • Klein, Florian; Nogueira, Lilian; Nishimura, Yoshiaki
  • The Journal of Experimental Medicine, Vol. 211, Issue 12
  • DOI: 10.1084/jem.20141050

Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex
journal, November 2014

  • Sok, Devin; van Gils, Marit J.; Pauthner, Matthias
  • Proceedings of the National Academy of Sciences, Vol. 111, Issue 49
  • DOI: 10.1073/pnas.1415789111

Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
journal, July 2010

Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies
journal, November 2009

  • Seaman, M. S.; Janes, H.; Hawkins, N.
  • Journal of Virology, Vol. 84, Issue 3
  • DOI: 10.1128/JVI.02108-09

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
journal, April 2013

  • Liao, Hua-Xin; Lynch, Rebecca; Zhou, Tongqing
  • Nature, Vol. 496, Issue 7446
  • DOI: 10.1038/nature12053

The Toxicity of Poisons Applied Jointly1
journal, August 1939

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
journal, October 2012

  • Klein, Florian; Halper-Stromberg, Ariel; Horwitz, Joshua A.
  • Nature, Vol. 492, Issue 7427
  • DOI: 10.1038/nature11604

Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo
journal, August 2014

  • Rudicell, R. S.; Kwon, Y. D.; Ko, S. -Y.
  • Journal of Virology, Vol. 88, Issue 21
  • DOI: 10.1128/JVI.02213-14

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
journal, August 2015

A quantitative basis for antiretroviral therapy for HIV-1 infection
journal, February 2012

  • Jilek, Benjamin L.; Zarr, Melissa; Sampah, Maame E.
  • Nature Medicine, Vol. 18, Issue 3
  • DOI: 10.1038/nm.2649

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
journal, September 2009

Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals
journal, January 2010

Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
journal, February 2014

Structural definition of a conserved neutralization epitope on HIV-1 gp120
journal, February 2007

Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity
journal, February 2014

  • Cimbro, R.; Gallant, T. R.; Dolan, M. A.
  • Proceedings of the National Academy of Sciences, Vol. 111, Issue 8
  • DOI: 10.1073/pnas.1314718111

Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes
journal, December 2014

  • Kong, Rui; Louder, Mark K.; Wagh, Kshitij
  • Journal of Virology, Vol. 89, Issue 5
  • DOI: 10.1128/JVI.03136-14

A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
journal, January 1993

In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer
journal, April 2021

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
text, January 2013

  • Jenny, McDowell,; Quino, Maduro,; Jiang, Zhu,
  • The University of North Carolina at Chapel Hill University Libraries
  • DOI: 10.17615/krmn-eg43

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors
text, January 2015

  • Aliaksandr, Druz,; F., Scheid, Johannes; R., Burton, Dennis
  • The University of North Carolina at Chapel Hill University Libraries
  • DOI: 10.17615/gy1k-dg87

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
text, January 2009

  • J., Hessell, A.; P., Poignard,; M., Hunter,
  • Nature Publishing Group
  • DOI: 10.5167/uzh-30535

Functional consequences of allotypic polymorphisms in human immunoglobulin G subclasses
journal, July 2022

Structural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
journal, February 2014

Broadly Neutralizing Antibodies and Viral Inducers Decrease Rebound from HIV-1 Latent Reservoirs in Humanized Mice
journal, August 2014

Broadly Neutralizing Anti-HIV-1 Antibodies Require Fc Effector Functions for In Vivo Activity
journal, September 2014

Natural Evolution of Broadly Neutralizing Antibodies
journal, April 2015

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors
journal, June 2015

A Blueprint for HIV Vaccine Discovery
journal, October 2012

Broadly Neutralizing Anti-HIV Antibody 4E10 Recognizes a Helical Conformation of a Highly Conserved Fusion-Associated Motif in gp41
journal, February 2005

Human Antibodies that Neutralize HIV-1: Identification, Structures, and B Cell Ontogenies
journal, September 2012

A method for identification of HIV gp140 binding memory B cells in human blood
journal, April 2009

  • Scheid, Johannes F.; Mouquet, Hugo; Feldhahn, Niklas
  • Journal of Immunological Methods, Vol. 343, Issue 2
  • DOI: 10.1016/j.jim.2008.11.012

Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1
journal, July 2014

  • Sarzotti-Kelsoe, Marcella; Bailer, Robert T.; Turk, Ellen
  • Journal of Immunological Methods, Vol. 409
  • DOI: 10.1016/j.jim.2013.11.022

Structural definition of a conserved neutralization epitope on HIV-1 gp120
journal, February 2007

Fc receptor but not complement binding is important in antibody protection against HIV
journal, September 2007

  • Hessell, Ann J.; Hangartner, Lars; Hunter, Meredith
  • Nature, Vol. 449, Issue 7158
  • DOI: 10.1038/nature06106

Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
journal, March 2009

  • Scheid, Johannes F.; Mouquet, Hugo; Feldhahn, Niklas
  • Nature, Vol. 458, Issue 7238
  • DOI: 10.1038/nature07930

Broad neutralization coverage of HIV by multiple highly potent antibodies
journal, September 2011

  • Walker, Laura M.; Huber, Michael; Doores, Katie J.
  • Nature, Vol. 477, Issue 7365
  • DOI: 10.1038/nature10373

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
journal, November 2011

  • McLellan, Jason S.; Pancera, Marie; Carrico, Chris
  • Nature, Vol. 480, Issue 7377
  • DOI: 10.1038/nature10696

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
journal, September 2012

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice
journal, October 2012

  • Klein, Florian; Halper-Stromberg, Ariel; Horwitz, Joshua A.
  • Nature, Vol. 492, Issue 7427
  • DOI: 10.1038/nature11604

Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
journal, April 2013

  • Liao, Hua-Xin; Lynch, Rebecca; Zhou, Tongqing
  • Nature, Vol. 496, Issue 7446
  • DOI: 10.1038/nature12053

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys
journal, October 2013

  • Barouch, Dan H.; Whitney, James B.; Moldt, Brian
  • Nature, Vol. 503, Issue 7475
  • DOI: 10.1038/nature12744

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface
journal, September 2014

  • Huang, Jinghe; Kang, Byong H.; Pancera, Marie
  • Nature, Vol. 515, Issue 7525
  • DOI: 10.1038/nature13601

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
journal, August 2014

  • Ko, Sung-Youl; Pegu, Amarendra; Rudicell, Rebecca S.
  • Nature, Vol. 514, Issue 7524
  • DOI: 10.1038/nature13612

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117
journal, April 2015

  • Caskey, Marina; Klein, Florian; Lorenzi, Julio C. C.
  • Nature, Vol. 522, Issue 7557
  • DOI: 10.1038/nature14411

B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study
journal, May 2012

  • Haynes, Barton F.; Kelsoe, Garnett; Harrison, Stephen C.
  • Nature Biotechnology, Vol. 30, Issue 5
  • DOI: 10.1038/nbt.2197

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
journal, June 2009

  • Hessell, Ann J.; Poignard, Pascal; Hunter, Meredith
  • Nature Medicine, Vol. 15, Issue 8
  • DOI: 10.1038/nm.1974

A quantitative basis for antiretroviral therapy for HIV-1 infection
journal, February 2012

  • Jilek, Benjamin L.; Zarr, Melissa; Sampah, Maame E.
  • Nature Medicine, Vol. 18, Issue 3
  • DOI: 10.1038/nm.2649

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
journal, June 2008

  • Shen, Lin; Peterson, Susan; Sedaghat, Ahmad R.
  • Nature Medicine, Vol. 14, Issue 7
  • DOI: 10.1038/nm1777

Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning
journal, August 2013

  • Kwong, Peter D.; Mascola, John R.; Nabel, Gary J.
  • Nature Reviews Immunology, Vol. 13, Issue 9
  • DOI: 10.1038/nri3516

Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120
journal, May 2013

  • Kong, Leopold; Lee, Jeong Hyun; Doores, Katie J.
  • Nature Structural & Molecular Biology, Vol. 20, Issue 7
  • DOI: 10.1038/nsmb.2594

Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo
journal, October 2012

  • Moldt, B.; Rakasz, E. G.; Schultz, N.
  • Proceedings of the National Academy of Sciences, Vol. 109, Issue 46
  • DOI: 10.1073/pnas.1214785109

Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies
journal, October 2012

  • Mouquet, H.; Scharf, L.; Euler, Z.
  • Proceedings of the National Academy of Sciences, Vol. 109, Issue 47
  • DOI: 10.1073/pnas.1217207109

Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9
journal, February 2013

  • Julien, Jean-Philippe; Lee, Jeong Hyun; Cupo, Albert
  • Proceedings of the National Academy of Sciences, Vol. 110, Issue 11
  • DOI: 10.1073/pnas.1217537110

Tyrosine sulfation in the second variable loop (V2) of HIV-1 gp120 stabilizes V2-V3 interaction and modulates neutralization sensitivity
journal, February 2014

  • Cimbro, R.; Gallant, T. R.; Dolan, M. A.
  • Proceedings of the National Academy of Sciences, Vol. 111, Issue 8
  • DOI: 10.1073/pnas.1314718111

HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice
journal, September 2013

  • Horwitz, J. A.; Halper-Stromberg, A.; Mouquet, H.
  • Proceedings of the National Academy of Sciences, Vol. 110, Issue 41
  • DOI: 10.1073/pnas.1315295110

Statistical significance for genomewide studies
journal, July 2003

  • Storey, J. D.; Tibshirani, R.
  • Proceedings of the National Academy of Sciences, Vol. 100, Issue 16, p. 9440-9445
  • DOI: 10.1073/pnas.1530509100

Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein
journal, July 2012

  • Klein, Florian; Gaebler, Christian; Mouquet, Hugo
  • The Journal of Experimental Medicine, Vol. 209, Issue 8
  • DOI: 10.1084/jem.20120423

Enhanced HIV-1 immunotherapy by commonly arising antibodies that target virus escape variants
journal, November 2014

  • Klein, Florian; Nogueira, Lilian; Nishimura, Yoshiaki
  • The Journal of Experimental Medicine, Vol. 211, Issue 12
  • DOI: 10.1084/jem.20141050

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults: VRC01 HIV-1 mAb in healthy adults
journal, September 2015

  • Ledgerwood, J. E.; Coates, E. E.; Yamshchikov, G.
  • Clinical & Experimental Immunology, Vol. 182, Issue 3
  • DOI: 10.1111/cei.12692

HIV-1 neutralizing antibodies: understanding nature's pathways
journal, June 2013

  • Mascola, John R.; Haynes, Barton F.
  • Immunological Reviews, Vol. 254, Issue 1
  • DOI: 10.1111/imr.12075

The Toxicity of Poisons Applied Jointly1
journal, August 1939

Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target
journal, September 2009

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding
journal, July 2011

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing
journal, August 2011

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield
journal, October 2011

Antibodies in HIV-1 Vaccine Development and Therapy
journal, September 2013

Immunologic strategies for HIV-1 remission and eradication
journal, July 2014

Promiscuous Glycan Site Recognition by Antibodies to the High-Mannose Patch of gp120 Broadens Neutralization of HIV
journal, May 2014

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor
journal, July 2014

Glycan Microheterogeneity at the PGT135 Antibody Recognition Site on HIV-1 gp120 Reveals a Molecular Mechanism for Neutralization Resistance
journal, April 2015

  • Pritchard, Laura K.; Spencer, Daniel I. R.; Royle, Louise
  • Journal of Virology, Vol. 89, Issue 13
  • DOI: 10.1128/jvi.00230-15

A Combination of Broadly Neutralizing HIV-1 Monoclonal Antibodies Targeting Distinct Epitopes Effectively Neutralizes Variants Found in Early Infection
journal, July 2012

  • Goo, L.; Jalalian-Lechak, Z.; Richardson, B. A.
  • Journal of Virology, Vol. 86, Issue 19
  • DOI: 10.1128/jvi.01414-12

HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes
journal, January 2012

  • Doria-Rose, N. A.; Louder, M. K.; Yang, Z.
  • Journal of Virology, Vol. 86, Issue 6
  • DOI: 10.1128/jvi.06745-11

The Role of Antibodies in HIV Vaccines
journal, March 2010

Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals
journal, January 2010

Antibody to gp41 MPER Alters Functional Properties of HIV-1 Env without Complete Neutralization
journal, July 2014

Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies
journal, August 2015

Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques
text, January 2009

  • J., Hessell, A.; P., Poignard,; M., Hunter,
  • Nature Publishing Group
  • DOI: 10.5167/uzh-30535
    Sort by:
    [ × clear filter / sort ]

    Works referencing / citing this record:

    Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies
    journal, March 2017

    Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1
    journal, November 2019

    • Moshoette, Tumelo; Ali, Stuart Alvaro; Papathanasopoulos, Maria Antonia
    • Retrovirology, Vol. 16, Issue 1
    • DOI: 10.1186/s12977-019-0493-y

    Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope
    journal, October 2019

    • van Dorsten, Rebecca T.; Lambson, Bronwen E.; Wibmer, Constantinos Kurt
    • Journal of Virology, Vol. 94, Issue 2
    • DOI: 10.1128/jvi.01533-19

    Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention
    journal, January 2017

    • Brady, Jacqueline M.; Baltimore, David; Balazs, Alejandro B.
    • Immunological Reviews, Vol. 275, Issue 1
    • DOI: 10.1111/imr.12478

    Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity
    journal, February 2018

    Pharmaceutical Approaches to HIV Treatment and Prevention
    journal, July 2018

    • Yavuz, Burcin; Morgan, Jessica L.; Showalter, Laura
    • Advanced Therapeutics, Vol. 1, Issue 6
    • DOI: 10.1002/adtp.201800054

    Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time
    journal, October 2017

    Landscape review of current HIV ‘kick and kill’ cure research - some kicking, not enough killing
    journal, August 2017

    • Thorlund, Kristian; Horwitz, Marc S.; Fife, Brian T.
    • BMC Infectious Diseases, Vol. 17, Issue 1
    • DOI: 10.1186/s12879-017-2683-3

    Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity
    journal, October 2016

    • VanBlargan, Laura A.; Goo, Leslie; Pierson, Theodore C.
    • Microbiology and Molecular Biology Reviews, Vol. 80, Issue 4
    • DOI: 10.1128/mmbr.00024-15

    Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
    journal, January 2018

    Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir
    journal, September 2019

    When two are better than one: Modeling the mechanisms of antibody mixtures
    journal, February 2020

    • Einav, Tal; Bloom, Jesse D.
    • PLOS Computational Biology
    • DOI: 10.1101/808394

    Adeno-associated virus gene delivery of broadly neutralizing antibodies as prevention and therapy against HIV-1
    journal, October 2018

    Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time
    journal, November 2018

    • Stefic, Karl; Bouvin-Pley, Mélanie; Essat, Asma
    • Journal of Virology, Vol. 93, Issue 2
    • DOI: 10.1128/jvi.01492-18

    Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections
    journal, March 2018

    Increasing the Clinical Potential and Applications of Anti-HIV Antibodies
    journal, November 2017

    Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization
    journal, July 2016

    Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development
    journal, January 2017

    • Bonsignori, Mattia; Liao, Hua-Xin; Gao, Feng
    • Immunological Reviews, Vol. 275, Issue 1
    • DOI: 10.1111/imr.12509

    Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials
    journal, May 2018

    Use of broadly neutralizing antibodies for HIV-1 prevention
    journal, January 2017

    • Pegu, Amarendra; Hessell, Ann J.; Mascola, John R.
    • Immunological Reviews, Vol. 275, Issue 1
    • DOI: 10.1111/imr.12511

    Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?
    journal, June 2018

    Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting
    journal, January 2017

    Landscape review of current HIV ‘kick and kill’ cure research - some kicking, not enough killing
    text, January 2017

    • Thorlund, Kristian; Horwitz, Marc S.; Fife, Brian T.
    • BioMed Central
    • DOI: 10.14288/1.0355234

    Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies
    text, January 2017

    • Todd, Bradley,; Baptiste, Aussedat,; Amit, Kumar,
    • The University of North Carolina at Chapel Hill University Libraries
    • DOI: 10.17615/a0m6-td59

    Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting
    text, January 2017

    • Doria-Rose, Nicole A.; Altae-Tran, Han R.; Roark, Ryan S.
    • Columbia University
    • DOI: 10.7916/d8zw1rks

    When two are better than one: Modeling the mechanisms of antibody mixtures
    journal, May 2020

    Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization
    text, January 2016

    • E., Giorgi, Elena; S., Seaman, Michael; C., Montefiori, David
    • The University of North Carolina at Chapel Hill University Libraries
    • DOI: 10.17615/2f0r-b813

    Broadly Neutralizing Antibodies as Treatment: Effects on Virus and Immune System
    journal, March 2017

    Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody
    journal, February 2018

    HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
    journal, August 2019

    Structural Basis for Broad HIV-1 Neutralization by the MPER-Specific Human Broadly Neutralizing Antibody LN01
    journal, November 2019

    AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region
    journal, September 2019

    • van den Berg, Fiona T.; Makoah, Nigel A.; Ali, Stuart A.
    • Molecular Therapy - Methods & Clinical Development, Vol. 14
    • DOI: 10.1016/j.omtm.2019.06.002

    Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial
    journal, April 2019

    Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies
    journal, January 2016

    • Fuchs, Sebastian P.; Desrosiers, Ronald C.
    • Molecular Therapy - Methods & Clinical Development, Vol. 3
    • DOI: 10.1038/mtm.2016.68

    Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity
    journal, February 2018

    Broad and potent cross clade neutralizing antibodies with multiple specificities in the plasma of HIV-1 subtype C infected individuals
    journal, April 2017

    • Cheedarla, Narayanaiah; Precilla, K. Lucia; Babu, Hemalatha
    • Scientific Reports, Vol. 7, Issue 1
    • DOI: 10.1038/srep46557

    Engineering antibody-like inhibitors to prevent and treat HIV-1 infection
    journal, May 2017

    Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development
    journal, January 2017

    • Bonsignori, Mattia; Liao, Hua-Xin; Gao, Feng
    • Immunological Reviews, Vol. 275, Issue 1
    • DOI: 10.1111/imr.12509

    Polyvalent vaccine approaches to combat HIV-1 diversity
    journal, January 2017

    • Korber, Bette; Hraber, Peter; Wagh, Kshitij
    • Immunological Reviews, Vol. 275, Issue 1
    • DOI: 10.1111/imr.12516

    Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now?
    journal, June 2018

    Engineering multi-specific antibodies against HIV-1
    journal, August 2018

    Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1
    journal, November 2019

    • Moshoette, Tumelo; Ali, Stuart Alvaro; Papathanasopoulos, Maria Antonia
    • Retrovirology, Vol. 16, Issue 1
    • DOI: 10.1186/s12977-019-0493-y

    Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials
    journal, February 2020

    Prospects for passive immunity to prevent HIV infection
    journal, November 2017

    Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
    journal, January 2018

    Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization
    journal, July 2016

    Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting
    journal, January 2017

    Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success
    journal, January 2017

    • Jaworski, Juan Pablo; Vendrell, Alejandrina; Chiavenna, Sebastián Matias
    • Frontiers in Immunology, Vol. 7
    • DOI: 10.3389/fimmu.2016.00661

    Long-Acting HIV Treatment and Prevention: Closer to the Threshold
    journal, June 2017

      Sort by:
      [ × clear filter / sort ]

      Similar Records in DOE PAGES and OSTI.GOV collections: